前列地尔联合羟苯磺酸钙治疗慢性肾衰竭的临床观察

目的:观察前列地尔联合羟苯磺酸钙治疗慢性肾衰竭(CRF)的临床效果。方法:选择在我院肾内科住院的60例CRF患者,随机分为治疗组(30例)和对照组(30例)。对照组仅给予常规治疗,治疗组在常规治疗的基础上加用前列地尔注射液(10μg,静脉滴注,qd)和羟苯磺酸钙胶囊(500mg,口服,tid)治疗。观察2组治疗前后肾功能(血清尿素氮(BUN)、血肌酐(Scr)、血尿酸(UA)、24h尿蛋白定量、肌酐清除率(Ccr))、血液流变学参数(全血低切黏度、全血高切黏度、血浆黏度)及血脂(总胆固醇(T-CHO)、甘油三酯(TG))水平的变化,并观察不良反应。结果:治疗2周和4周后,治疗组BUN、Scr、UA、24h尿蛋白定量显著下降,Ccr显著上升,且显著优于治疗前和对照组同期,差异有统计学意义(P<0.05),且治疗组全血低切黏度、全血高切黏度、血浆黏度和T-CHO、TG较治疗前及对照组同期显著降低,差异有统计学意义(P<0.05)。2组未见明显不良反应发生。结论:CRF患者在常规治疗基础上应用前列地尔联合羟苯磺酸钙治疗安全、有效。

Clinical Observation of Alprostadil Combined with Calcium Dobesilate in the Treatment of Chronic Renal Failure

OBJECTIVE： To observe the clinical efficacy of alprostadil combined with calcium dobesilate in the treatment of chronic renal failure （CRF）. METHODS： 60 CRF patients in nephrology department of our hospital were collected and randomly divided into treatment group and control group （n----30）. On the basis of the conventional treatment, treatment group was additional- ly treated with Alprostadil injection （10 Ixg, intravenous dripping, qd） and calcium dobesilate （500 mg, orally, tid）, while only conventional treatment was performed in control group. Renal function index （BUN, Scr, UA, 24 h urinary protein, Ccr）, blood rheology parameters （BVL, BVH, PV） and blood lipid （T-CHO, TG） level were observed in 2 groups before and after treatment and adverse drug reaction was also observed. RESULTS： 2 weeks and 4 weeks later, levels of BUN, Scr, UA and 24 h urinary protein quantitative in treatment group were significantly decreased, while Ccr level was increased significantly, and renal function index of treatment group were significantly better than before treatment and corresponding period of control group （P〈0.05） ; BVL, BVH, PV, T-CHO and TG of treatment group were decreased significantly, compared with before treatment and correspond- ing period of control group （P〈0.05）. No obvious adverse drug reaction was found in 2 groups. CONCLUSION： Based on conven- tional treatment, combination of alprostadil and calcium dobesilate is a safe and effective treatment for CRF patients.